profit from every €100 of sales.
€0€100
Ipsen
€163.40+2.96% today
+36.1% since Dec 18, 25
1-year low €116.101-year high €172.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €30.37 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Ipsen sold, what it kept, and what it did with the cash.
Sales went from €3.16 billion in 2022 to €3.93 billion in 2025, with €444 million of profit last year.
SalesProfit
Ipsen handed back 23% of the cash it generated last year.
Buybacks €68M€116M
Free cash flow 2025€810M
Bought back its own shares€68M
Paid as dividends€116M
Cash vs. debt€1.5B vs. €867M
Ipsen vs. similar companies
Ipsen grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Ipsen | 30.4× · Expensive | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Ipsen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,157 | 3,306 | 3,575 | 3,929 | |
| 2,629 | 2,735 | 2,870 | 3,178 | |
| 871 | 611 | 688 | 945 | |
| 1,073 | 1,007 | 1,179 | 1,248 | |
| 649 | 644 | 346 | 444 | |
| 7.81 | 7.73 | 4.15 | 5.32 | |
| 83.3% | 82.7% | 80.3% | 80.9% | |
| 27.6% | 18.5% | 19.3% | 24.1% | |
| 20.5% | 19.5% | 9.7% | 11.3% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5,615 | 6,323 | 6,439 | 6,938 |
| Cash | 1,169 | 528 | 678 | 1,526 |
| Total debt | 613 | 374 | 427 | 867 |
| Total liabilities | 2,271 | 2,499 | 2,257 | 2,601 |
| 3,344 | 3,825 | 4,182 | 4,336 | |
| 83 | 83 | 83 | 83 | |
| 14.0% | 14.3% | 7.7% | 9.0% | |
| 19.4% | 16.8% | 8.3% | 10.2% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 971 | 866 | 916 | 1,138 | |
| 253 | 189 | 783 | 329 | |
| 719 | 677 | 133 | 810 | |
| Dividends paid | 99 | 100 | 100 | 116 |
| 11 | 40 | 37 | 68 | |
| 27 | 30 | 30 | 39 |
Valuation
- 30.4×
- –
- –
- 3.0×
- 3.4×
- 16.6×
- 10.3×
- 6.0%
- 3.3%
- 0.9%
Profitability
- 80.9%
- 24.1%
- 11.3%
- –
- 9.0%
- 11.2%
- –
- –
- –
- –
Growth
- +7.6%
- −12.0%
- –
- –
- +0.1%
Financial health
- -0.5×
- 0.20
- –
- 14.1×
- 1.96
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 33%of 948
Top 17%of 871
Bottom 46%of 560
Bottom 37%of 868
Top 16%of 985
0.9%of the share price, paid each year
On $1,000 invested$9a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
26.2% of its profit
Room to growStretchedMore than it earns: 14.4%
News
Ipsen raises 2026 sales growth outlook to 23% after Q3 sales jump 28%Seeking Alpha · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
65Pass
Benjamin Graham
49No pass
Philip Fisher
57No pass
Peter Lynch
33No pass
Joel Greenblatt
25No pass
Charlie Munger
58No pass
Terry Smith
57No pass
Questions about Ipsen
Is Ipsen a good stock to buy?
A solid business, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ipsen AI analysis
What does Ipsen do?
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Paris, France, with 5,535 employees.
Does Ipsen pay a dividend?
Yes. At today's price the dividend is 0.9% a year, about 26% of its yearly profit. In 2025 it paid out €116 million in dividends.
Is Ipsen stock halal?
Yes. Ipsen passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
Who are Ipsen's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Ipsen's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.